Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle A Davis

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Applied and Environmental Microbiology|August 10, 2020
Genetic Reprogramming of the Ergot Alkaloid Pathway of Metarhizium brunneumKyle A Davis, Jessi K Sampson, Daniel G Panaccione
Applied Microbiology (Basel, Switzerland)|July 26, 2024
A Major Facilitator Superfamily Transporter Contributes to Ergot Alkaloid Accumulation but Not Secretion in <i>Aspergillus leporis</i>Abigail M Jones, Kyle A Davis, Daniel G Panaccione
Clinical Drug Investigation|November 23, 2019
Bleeding Risk of Therapeutic Unfractionated Heparin and Low Molecular Weight Heparin in Patients with CirrhosisKatherine L Summers, Kyle A Davis, Sarah A Nisly
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 11, 2019
Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centreKyle A Davis, Joseph R Stanek, Amy L Dunn
Applied and Environmental Microbiology|July 11, 2023
Two Satellite Gene Clusters Enhance Ergot Alkaloid Biosynthesis Capacity of Aspergillus <i>leporis</i>Kyle A Davis, Abigail M Jones, Daniel G Panaccione
Journal of Pharmacy Practice|November 23, 2012
Optimizing transition of care through the facilitation of a pharmacist-managed deep vein thrombosis treatment programKyle A Davis, Marta A Miyares, Venessa S Price-Goodnow
Pharmacotherapy|August 11, 2019
Treatment of Helicobacter pylori in Special Patient PopulationsCynthia T Nguyen, Kyle A Davis, Sarah A Nisly, et al.
Journal of Global Antimicrobial Resistance|August 8, 2019
Oral antibiotics for the treatment of Gram-negative bloodstream infections: A retrospective comparison of three antibiotic classesSarah A Nisly, Dominique L McClain, Amy G Fillius, et al.
Journal of Thrombosis and Thrombolysis|March 17, 2021
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysisSarah A Nisly, Alexandra E Mihm, Chris Gillette, et al.
Diagnostic Microbiology and Infectious Disease|August 2, 2021
Impact of Chronic Hepatitis C virus co-infection on outcomes of infective endocarditis in people who inject drugsChloe Tom, Glen Huang, Alexander J Kovalic, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Applied and Environmental Microbiology|August 10, 2020
Genetic Reprogramming of the Ergot Alkaloid Pathway of Metarhizium brunneumKyle A Davis, Jessi K Sampson, Daniel G Panaccione
Applied Microbiology (Basel, Switzerland)|July 26, 2024
A Major Facilitator Superfamily Transporter Contributes to Ergot Alkaloid Accumulation but Not Secretion in <i>Aspergillus leporis</i>Abigail M Jones, Kyle A Davis, Daniel G Panaccione
Clinical Drug Investigation|November 23, 2019
Bleeding Risk of Therapeutic Unfractionated Heparin and Low Molecular Weight Heparin in Patients with CirrhosisKatherine L Summers, Kyle A Davis, Sarah A Nisly
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 11, 2019
Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centreKyle A Davis, Joseph R Stanek, Amy L Dunn
Applied and Environmental Microbiology|July 11, 2023
Two Satellite Gene Clusters Enhance Ergot Alkaloid Biosynthesis Capacity of Aspergillus <i>leporis</i>Kyle A Davis, Abigail M Jones, Daniel G Panaccione
Journal of Pharmacy Practice|November 23, 2012
Optimizing transition of care through the facilitation of a pharmacist-managed deep vein thrombosis treatment programKyle A Davis, Marta A Miyares, Venessa S Price-Goodnow
Pharmacotherapy|August 11, 2019
Treatment of Helicobacter pylori in Special Patient PopulationsCynthia T Nguyen, Kyle A Davis, Sarah A Nisly, et al.
Journal of Global Antimicrobial Resistance|August 8, 2019
Oral antibiotics for the treatment of Gram-negative bloodstream infections: A retrospective comparison of three antibiotic classesSarah A Nisly, Dominique L McClain, Amy G Fillius, et al.
Journal of Thrombosis and Thrombolysis|March 17, 2021
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysisSarah A Nisly, Alexandra E Mihm, Chris Gillette, et al.
Diagnostic Microbiology and Infectious Disease|August 2, 2021
Impact of Chronic Hepatitis C virus co-infection on outcomes of infective endocarditis in people who inject drugsChloe Tom, Glen Huang, Alexander J Kovalic, et al.
Pageof 3